Lipopolysaccharide (LPS) Vagus nerve Vagus nerve stimulation Sympathetic nervous system Splanchnic anti-inflammatory pathway Inflammation Tumor necrosis factor α (TNF) Interleukin 10 (IL-10) Endotoxemia Greater splanchnic nerve A B S T R A C T Electrical stimulation of the vagus nerve (VNS) is a novel strategy used to treat inflammatory conditions. Therapeutic VNS activates both efferent and afferent fibers; however, the effects attributable to vagal afferent stimulation are unclear. Here, we tested if selective activation of afferent fibers in the abdominal vagus suppresses systemic inflammation. In urethane-anesthetized rats challenged with lipopolysaccharide (LPS, 60 µg/kg, i.v.), abdominal afferent VNS (2 Hz for 20 min) reduced plasma tumor necrosis factor alpha (TNF) levels 90 min later by 88% compared with unmanipulated animals. Pre-cutting the cervical vagi blocked this anti-inflammatory action. Interestingly, the surgical procedure to expose and prepare the abdominal vagus for afferent stimulation ('vagal manipulation') also had an anti-inflammatory action. Levels of the anti-inflammatory cytokine IL-10 were inversely related to those of TNF. Prior bilateral section of the splanchnic sympathetic nerves reversed the anti-inflammatory actions of afferent VNS and vagal manipulation. Sympathetic efferent activity in the splanchnic nerve was shown to respond reflexly to abdominal vagal afferent stimulation. These data demonstrate that experimentally activating abdominal vagal afferent fibers suppresses systemic inflammation, and that the efferent neural pathway for this action is in the splanchnic sympathetic nerves.
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Introduction
Vagal nerve stimulation (VNS) is now considered a promising therapeutic tool to treat inflammatory diseases, including cases that are not responsive to classic pharmaceutical treatments (Bonaz et al., 2016b) . VNS can suppress both local (Borovikova et al., 2000a ) and systemic inflammation (Borovikova et al., 2000b) . Selectively stimulating efferent fibers in the vagus has this action, and many studies have shown that it suppresses the levels of tumor necrosis factor α (TNF), a key mediator of the inflammatory response, in endotoxemia (intravenous lipopolysaccharide; LPS) (Pavlov and Tracey, 2015; RosasBallina et al., 2008; Vida et al., 2011a) . That anti-inflammatory action has been shown to depend upon a number of factors including the spleen, splenic nerves, a subset of T cells and alpha-7 nicotinic receptors (Pavlov and Tracey, 2015; Rosas-Ballina et al., 2011) .
Therapeutic VNS, however, activates both efferent and afferent fibers in the vagus. At least 80% of these fibers are afferent (Prechtl and Powley, 1990) . The effects of this form of stimulation have wide ranging actions, including suppression of inflammation in the gut (Bonaz et al., 2016a) and joints (Koopman et al., 2016) . In these cases, the relative contributions of vagal afferent and efferent fibers are unclear. While the anti-inflammatory effects of vagal efferent stimulation are well described (see above), those of vagal afferent stimulation are only now emerging. It is already evident that the anti-inflammatory actions of vagal afferent stimulation must be mediated by different mechanisms than those of vagal efferent stimulation. An incidental finding reported by Vida and colleagues was that stimulating the intact vagus (activating both afferent and efferent pathways) had a systemic anti-inflammatory action even in alpha-7 nicotinic receptor knockout mice (Vida et al., 2011a) in which selective vagal efferent stimulation is ineffective (Vida et al., 2011a; Wang et al., 2003) . Afferent VNS has also been shown to
